Cargando…

Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery

BACKGROUND: There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribute to the progression of CRLM. A main glycolytic enzyme pyruvate Kinase M2 (PKM2...

Descripción completa

Detalles Bibliográficos
Autores principales: Long, Li, Xiong, Wei, Lin, Fenwang, Hou, Jiazhen, Chen, Guihua, Peng, Taoxing, He, Yihao, Wang, Rui, Xu, Qin, Huang, Yongzhuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170793/
https://www.ncbi.nlm.nih.gov/pubmed/37161591
http://dx.doi.org/10.1186/s13046-023-02688-z
_version_ 1785039295490293760
author Long, Li
Xiong, Wei
Lin, Fenwang
Hou, Jiazhen
Chen, Guihua
Peng, Taoxing
He, Yihao
Wang, Rui
Xu, Qin
Huang, Yongzhuo
author_facet Long, Li
Xiong, Wei
Lin, Fenwang
Hou, Jiazhen
Chen, Guihua
Peng, Taoxing
He, Yihao
Wang, Rui
Xu, Qin
Huang, Yongzhuo
author_sort Long, Li
collection PubMed
description BACKGROUND: There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribute to the progression of CRLM. A main glycolytic enzyme pyruvate Kinase M2 (PKM2) is highly expressed in colorectal cancer and CRLM, and thus can be a potential therapeutic target. METHODS: A therapeutic strategy was proposed and the shikonin-loaded and hyaluronic acid-modified MPDA nanoparticles (SHK@HA-MPDA) were designed for CRLM therapy via PKM2 inhibition for immunometabolic reprogramming. The treatment efficacy was evaluated in various murine models with liver metastasis of colorectal tumor. RESULTS: SHK@HA-MPDA achieved tumor-targeted delivery via hyaluronic acid-mediated binding with the tumor-associated CD44, and efficiently arrested colorectal tumor growth. The inhibition of PKM2 by SHK@HA-MPDA led to the remodeling of the tumor immune microenvironment and reversing EMT by lactate abatement and the suppression of TGFβ signaling; the amount of cytotoxic effector CD8(+) T cells was increased while the immunosuppressive MDSCs decreased. CONCLUSION: The work provided a promising targeted delivery strategy for CRLM treatment by regulating glycolysis, EMT, and anticancer immunity. GRAPHIC ABSTRACT: An immunometabolic strategy for treating colorectal cancer liver metastases using the shikonin-loaded, hyaluronic acid-modified mesoporous polydopamine nanoparticles (SHK@HA-MPDA) via glycolysis inhibition, anticancer immunity activation, and EMT reversal. SHK@HA-MPDA can inhibit cytoplasmic PKM2 and glycolysis of the tumor and reduce lactate flux, and then activate the DCs and remodel the tumor immune microenvironment. The reduced lactate flux can reduce MDSC migration and suppress EMT. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02688-z.
format Online
Article
Text
id pubmed-10170793
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-101707932023-05-11 Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery Long, Li Xiong, Wei Lin, Fenwang Hou, Jiazhen Chen, Guihua Peng, Taoxing He, Yihao Wang, Rui Xu, Qin Huang, Yongzhuo J Exp Clin Cancer Res Research BACKGROUND: There are few effective medications for treating colorectal cancer and liver metastases (CRLM). The interactions among glycolysis, epithelial-mesenchymal transition (EMT), and immune microenvironment contribute to the progression of CRLM. A main glycolytic enzyme pyruvate Kinase M2 (PKM2) is highly expressed in colorectal cancer and CRLM, and thus can be a potential therapeutic target. METHODS: A therapeutic strategy was proposed and the shikonin-loaded and hyaluronic acid-modified MPDA nanoparticles (SHK@HA-MPDA) were designed for CRLM therapy via PKM2 inhibition for immunometabolic reprogramming. The treatment efficacy was evaluated in various murine models with liver metastasis of colorectal tumor. RESULTS: SHK@HA-MPDA achieved tumor-targeted delivery via hyaluronic acid-mediated binding with the tumor-associated CD44, and efficiently arrested colorectal tumor growth. The inhibition of PKM2 by SHK@HA-MPDA led to the remodeling of the tumor immune microenvironment and reversing EMT by lactate abatement and the suppression of TGFβ signaling; the amount of cytotoxic effector CD8(+) T cells was increased while the immunosuppressive MDSCs decreased. CONCLUSION: The work provided a promising targeted delivery strategy for CRLM treatment by regulating glycolysis, EMT, and anticancer immunity. GRAPHIC ABSTRACT: An immunometabolic strategy for treating colorectal cancer liver metastases using the shikonin-loaded, hyaluronic acid-modified mesoporous polydopamine nanoparticles (SHK@HA-MPDA) via glycolysis inhibition, anticancer immunity activation, and EMT reversal. SHK@HA-MPDA can inhibit cytoplasmic PKM2 and glycolysis of the tumor and reduce lactate flux, and then activate the DCs and remodel the tumor immune microenvironment. The reduced lactate flux can reduce MDSC migration and suppress EMT. [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13046-023-02688-z. BioMed Central 2023-05-10 /pmc/articles/PMC10170793/ /pubmed/37161591 http://dx.doi.org/10.1186/s13046-023-02688-z Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Long, Li
Xiong, Wei
Lin, Fenwang
Hou, Jiazhen
Chen, Guihua
Peng, Taoxing
He, Yihao
Wang, Rui
Xu, Qin
Huang, Yongzhuo
Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
title Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
title_full Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
title_fullStr Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
title_full_unstemmed Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
title_short Regulating lactate-related immunometabolism and EMT reversal for colorectal cancer liver metastases using shikonin targeted delivery
title_sort regulating lactate-related immunometabolism and emt reversal for colorectal cancer liver metastases using shikonin targeted delivery
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10170793/
https://www.ncbi.nlm.nih.gov/pubmed/37161591
http://dx.doi.org/10.1186/s13046-023-02688-z
work_keys_str_mv AT longli regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT xiongwei regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT linfenwang regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT houjiazhen regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT chenguihua regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT pengtaoxing regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT heyihao regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT wangrui regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT xuqin regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery
AT huangyongzhuo regulatinglactaterelatedimmunometabolismandemtreversalforcolorectalcancerlivermetastasesusingshikonintargeteddelivery